Why Does Ozempic Cause Pancreatitis? The Biology Behind This Rare but Serious Side Effect

What the Ozempic label says

The pancreatitis warning in the Ozempic prescribing information is written at the class level. It states that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including Ozempic [1].

It then gives prescribers a symptom list and an instruction: after starting the drug, observe patients for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain sometimes radiating to the back, with or without nausea or vomiting; if pancreatitis is suspected, discontinue Ozempic and initiate appropriate management [1].

The adverse reactions section lists acute and necrotizing pancreatitis, sometimes fatal, among postmarketing reports, where frequency cannot be estimated from voluntary reports [1]. No cause is named anywhere in the label's pancreatitis text.

How often it turns up

The pooled trial picture is reassuring. In the Ozempic glycemic-control trials, the label reports acute pancreatitis confirmed by adjudication in 7 Ozempic-treated patients (0.3 cases per 100 patient-years) versus 3 comparator-treated patients (0.2 cases per 100 patient-years) [1]. A meta-analysis of 21 randomized trials of GLP-1 receptor agonists, covering 99,599 patients, found no difference in pancreatitis between treated patients and controls [3]. A review of real-world data on liraglutide, semaglutide and tirzepatide likewise found no clear increase in severe events such as pancreatitis [4].

The picture is not uniform. In a meta-analysis of 4 randomized trials of subcutaneous semaglutide for obesity in 3,613 people without diabetes, serious adverse events were 1.6 times as likely with semaglutide (RR 1.60, 95% CI 1.24 to 2.07), and the serious events were mostly gastrointestinal and hepatobiliary disorders such as acute pancreatitis and cholelithiasis [6]. Ozempic's postmarketing reports cannot establish how often pancreatitis occurs [1].

One idea: a direct effect on the pancreas

Butler and colleagues argued that incretin-based drugs may promote acute pancreatitis and histological changes suggesting chronic pancreatitis, and noted that preclinical and epidemiological data on the question conflict [7].

One animal experiment used a different drug. Twenty Sprague-Dawley rats were studied for 75 days, ten given exendin-4 (exenatide) and ten used as controls; the treated animals had more pancreatic acinar inflammation, more pyknotic nuclei and higher serum lipase than controls [2]. A study of 20 rats and a GLP-1 receptor agonist that is not semaglutide cannot show what semaglutide does inside a human pancreas.

A 2021 review of semaglutide safety found no unexpected safety issues overall and described a favorable risk-benefit profile in type 2 diabetes [5].

Another thread: gallstones and the biliary tree

The Ozempic label carries a separate acute gallbladder disease warning: if cholelithiasis or cholecystitis is suspected, gallbladder studies are indicated [1]. A review of semaglutide safety concluded that the drug increases the risk of biliary disease, specifically cholelithiasis [5]. A pooled analysis of GLP-1 receptor agonist trials also found more gallbladder disorders than controls (+26%) [3].

Whether gallstones account for any of the pancreatitis cases reported with Ozempic is unknown; the label's pancreatitis text does not assign a cause to the cases it describes [1].

Where that leaves the question

Ozempic's label warns about pancreatitis because cases have been observed in people taking GLP-1 receptor agonists, including Ozempic [1]. Pooled randomized data show no difference in pancreatitis versus controls [3], while the evidence for direct pancreatic injury comes mainly from rodent work with a different drug [2]. The label's gallbladder warning is separate, and no cause is assigned to the pancreatitis cases [1].